Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has signed an agreement with ...
Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...
Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...
DUBLIN--(BUSINESS WIRE)--The "Global Molecular Diagnostics Market Report by Technology Application Product End Users Countries and Company Analysis 2024-2032" report has been added to ...
As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics' broadly validated diagnostic platforms, MyRisk Hereditary Cancer ...
Australian scientists have identified the key genetic drivers behind long COVID, revealing why some people continue to ...
Emerging markets, breakthrough technologies, and strategic M&A reshape competitive landscapeThe global molecular cytogenetics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback